The cost-effectiveness and value of information of three influenza vaccination dosing strategies for individuals with human immunodeficiency virus

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Nosyk, Bohdan ^a   Sharif, Behnam ^a   Sun, Huiying ^a   Cooper, Curtis ^a,b   Anis, Aslam H ^a,c  

^a Canadian HIV Trials Network   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FLUVIRAL; INFLUENZA VACCINE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; FEMALE; FLU LIKE SYNDROME; HOSPITAL COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SINGLE DRUG DOSE; VIRUS INHIBITION; VIRUS LOAD; CANADA; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; DRUG ADMINISTRATION; INFECTION CONTROL; INTRAMUSCULAR DRUG ADMINISTRATION; METHODOLOGY; MIDDLE AGED; PREVENTIVE HEALTH SERVICE; PROBABILITY; VIROLOGY;

ADULT; CANADA; COHORT STUDIES; COMMUNICABLE DISEASE CONTROL; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HUMANS; IMMUNIZATION PROGRAMS; INFLUENZA, HUMAN; INJECTIONS, INTRAMUSCULAR; MALE; MARKOV CHAINS; MIDDLE AGED;

EID: 82755170611     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027059     Document Type: Article

References (40)

1. Cooper C, Hutton B, Fergusson D, Mills E, Klein MB, et al. (2008) A review of influenza vaccine immunogenicity and efficacy in HIV-infected adults. Can J Infect Dis Med Microbiol 19 (6): 419-23.
2. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). CDC weekly report 99; 48 (RR-4): 1-28 Available from www.cdc.gov. Accessed March 2010.
3. Lin JC, Nichol KL, (2001) Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 161: 441-446.
4. Fine AD, Bridges CB, De Guzman AM, Glover L, Zeller B, et al. (2001) Influenza A among patients with human immunodeficiency virus: an outbreak of infection at a residential facility in New York City. Clin Infect Dis 32 (12): 1784-91.
5. Atashili J, Kalilani L, Adimora AA, (2006) Efficacy and clinical effectiveness of influenza vaccines in HIV-infected individuals: a meta-analysis. BMC Infect Dis 6: 138.
6. Anema A, Mills E, Montaner J, Brownstein JS, Cooper C, (2008) Efficacy of influenza vaccination in HIV-positive patients: a systematic review and meta-analysis. HIV Med 9 (1): 57-61.
7. Yamanaka H, Teruya K, Tanaka M, Kikuchi Y, Takahashi T, et al. (2005) Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr 39 (2): 167-73.
8. Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth R, (2000) Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 18 (26): 3040-9.
9. Cooper C, Thorne A, Klein M, Conway B, Boivin G, et al. (2011) Immunogenicity Is Not Improved by Increased Antigen Dose or Booster Dosing of Seasonal Influenza Vaccine in a Randomized Trial of HIV Infected Adults. PLoS One 6 (3): e17758.
10. May M, Sterne JA, Sabin C, Costagliola D, Justice AC, et al. (2007) Antiretroviral Therapy (ART) Cohort Collaboration. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS 21 (9): 1185-97.
11. Ramsey S, Willke R, Briggs A, Brown R, Buxton M, et al. (2005) Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health 8 (5): 521-33.
12. Humphreys EH, Change LW, Harris J, Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy (Review), http://www.thecochranelibrary.com. Accessed: May 2010.
13. Bansi LK, Benzie AA, Phillips AN, Portsmouth S, Hill T, et al. (2008) UK Collaborative HIV Cohort (UK CHIC) Study. Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression? AIDS 22 (3): 349-56.
14. Statistics Canada Table 105-0501, Health indicator profile, annual estimates, by age group and sex, Canada, provinces, territories, health regions (2007 boundaries) and peer groups, occasional (1209600 series). Available at: http://cansim2.statcan.gc.ca/cgi-win/cnsmcgi.pgm?LANG=E&RegTkt=&C2Sub=&C2DB=PRD&ROOTDIR=CII/&ResultT emplate = CII/CII_FLst&SrchVer = 2&ChunkSize = 50&CIITables = 2969, Accessed February 2009.
15. Dunning AJ, (2006) A model for immunological correlates of protection. Stat Med 25 (9): 1485-97.
16. Nauta JJ, Beyer WE, Osterhaus AD, (2009) On the relationship between mean antibody level, seroprotection and clinical protection from influenza. Biologicals 37: 216-221.
17. Soonawala D, Rimmelzwaan GF, Gelinck LB, Visser LG, Kroon FP, (2011) Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS One 6 (1): e16496.
18. Beyer WE, Palache AM, Lüchters G, Nauta J, Osterhaus AD, (2004) Seroprotection rate, mean fold increase, seroconversion rate: which parameter adequately expresses seroresponse to influenza vaccination? Virus Res 103 (1-2): 125-32.
19. Centre for Disease Control website- 2002-2009 influenza season. Available at: http://www.cdc.gov/flu/weekly/fluactivity.htm. Accessed January 2010.
20. Sullivan KM, Monto AS, Longini IM Jr, (1993) Estimates of the US health impact of influenza. Am J Public Health 1993; 83 (12): 1712-1716.
21. Scuffham PA, West PA, (2002) Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 20 (19-20): 2562-2578.
22. Myśliwska J, Trzonkowski P, Szmit E, Brydak LB, Machała M, et al. (2004) immunomodulating effect of influenza vaccination in the elderly differing in health status. Exp Gerontol 10: 1447-58.
23. Skowronski DM, Tweed SA, De Serres G, (2008) Rapid decline of influenza vaccine-induced antibody in the elderly: is it real, or is it relevant? J Infect Dis 197 (4): 490-502.
24. Riera M, Payeras A, Marcos MA, Viasus D, Farinas MC, et al. (2010) Clinical presentation and prognosis of the 2009 H1N1 influenza A infection in HIV-1-infected patients: a Spanish multicenter study. AIDS 24 (16): 2461-7.
25. Thompson WW, Weintraub E, Dhankhar P, Cheng PY, Brammer L, (2009) Estimates of US influenza-associated deaths made using four different methods. Influenza Other Respi Viruses 3 (1): 37-49.
26. Nosyk B, Sun H, Bansback N, Guh DP, Li X, et al. (2009) The concurrent validity and responsiveness of the health utilities index (HUI 3) among patients with advanced HIV/AIDS. Qual Life Res 18 (7): 815-24.
27. Anis AH, Nosyk B, Sun H, Guh DP, Bansback N, et al. (2009) Quality of life of patients with advanced HIV/AIDS: measuring the impact of both AIDS-defining events and non-AIDS serious adverse events. J Acquir Immune Defic Syndr 51 (5): 631-9.
28. Koopmanschap M, Burdorf A, Jacob K, Meerding WJ, Brouwer W, (2005) Measuring productivity changes in economic evaluation: setting the research agenda. Pharmacoeconomics 23 (1): 47-54.
29. Gebo KA, Fleishman JA, Conviser R, Hellinger J, Hellinger FJ, et al. (2010) Contemporary costs of HIV healthcare in the HAART era. AIDS 24: 2705-2715.
30. Briggs A, Claxton K, Sculpher M, (2006) Decision Modelling for Health Economic Evaluation London Oxford university press.
31. Singh S, Nosyk B, Sun H, Christenson J, Innes G, et al. (2008) Value of information of a clinical prediction rule: informing the efficient use of healthcare and health research resources. Int J Technol Assess Health Care 24 (1): 112-9.
32. Centre for Disease Control (CDC) website- Influenza vaccine price list. Available at: http://www.cdc.gov/vaccines/programs/vfc/cdc-vac-price-list.htm. Accessed May 2010.
33. British Columbia Medical Association BCMA guide to fees. https://www.bcma.org/publications-media/handbooks-guides. Accessed June 2009.
34. Palepu A, Tyndall MW, Leon H, Muller J, O'Shaughnessy MV, et al. (2001) Hospital utilization and costs in a cohort of injection drug users. CMAJ 165 (4): 415-20.
35. Public Health Agency of Canada Estimates of HIV Prevalence and Incidence in Canada, 2008 (http://www.phac-aspc.gc.ca/aids-sida/publication/survreport/estimat08-eng.php). Surveillance and Risk Assessment Division, Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada, 2008. Accessed May 2010.
36. Gafni A, Birch S, (2006) Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc Sci Med 62 (9): 2091-100.
37. Klein MB, Lu Y, DelBalso L, Coté S, Boivin G, (2007) Influenza virus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis 45 (2): 234-40.
38. Kim SY, Goldie SJ, (2008) Cost-effectiveness analyses of vaccination programmes: a focused review of modeling approaches. Pharmacoeconomics 26 (3): 191-215.
39. Nichol KL, (2008) Efficacy and effectiveness of influenza vaccination. Vaccine 26 (Suppl 4): D17-D22.
40. De Jong JC, Palache AM, Beyer WEP, Rimmelzwaan GF, Boon ACM, (2003) Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 115: 63-73.